TCRR stock forecast
Our latest prediction for TCR2 Therapeutics, Inc.'s stock price was made on the Dec. 19, 2019 when the stock price was at 16.10$.
In the short term (2weeks), TCRR's stock price should underperform the market by -7.14%. During that period the price should oscillate between -12.72% and +9.53%.
In the medium term (3months), TCRR's stock price should underperform the market by -16.71%. During that period the price should oscillate between -39.84% and +24.44%.Get email alerts
Create a solid portfolio with TCRR
About TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering t-cells for cancer therapy. The firm offers cancer therapy, t-cell biology, immunology and molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of t-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -4.01$ per share.
The book value per share is 7.62$
Three months stock forecastDec. 19, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|